Scientific research, design and development of personalized whole tumor-derived cell-based autologous immunotherapies for the treatment of cancers; providing a proprietary technology platform for the development of pharmaceutical products and devices featuring technology capable of eliciting anti-tumor responses via the release of tumor antigenic signatures and immunostimulatory factors that activate the adaptive immune system against tumor cells